Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors

References

• Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer 2014;86:78–84.
   PubMed Web of Science ®Google Scholar
• Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanana P. Lung cancer: biology and treatment options. Biochim Biophys Acta 2015;1856:189–210.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Al-Ansary GH, Elsayed ZM, et al. Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J Enzyme Inhib Med Chem 2021;36:987–99.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother 2021;134:111111.
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17:637–58.
   PubMed Web of Science ®Google Scholar
• Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 2016;44:42–50.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer 2018;124:53–64.
   PubMed Web of Science ®Google Scholar
• Soliman AM, Alqahtani AS, Ghorab M. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. J Enzyme Inhib Med Chem 2019;34:1030–40.
   PubMed Web of Science ®Google Scholar
• Milik SN, Lasheen DS, Serya RAT, et al. How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem 2017;142:131–51.
   PubMed Web of Science ®Google Scholar
• Singh SS, Mattheolabakis G, Gu X, et al. A grafted peptidomimetic for EGFR heterodimerization inhibition: implications in NSCLC models. Eur J Med Chem 2021;216:113312.
   PubMed Web of Science ®Google Scholar
• Ayati A, Moghimi S, Salarinejad S, et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 2020;99:103811.
   PubMed Web of Science ®Google Scholar
• Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016;13:209–27.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr., Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 2020;152:104609.
   PubMed Web of Science ®Google Scholar
• Ewes WA, Elmorsy MA, El-Messery SM, et al. Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: new class of EGFR-TK inhibitors. Bioorg Med Chem 2020;28:115373.
   PubMedGoogle Scholar
• Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, Non Exon 20 insertions, EGFR mutations. J Thorac Oncol 2021;16:764–73.
   PubMed Web of Science ®Google Scholar
• Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol 2018;14:1117–32.
   PubMed Web of Science ®Google Scholar
• Kim ES, Melosky B, Park K, et al. EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol 2021;17:2395–408.
   PubMed Web of Science ®Google Scholar
• Min HY, Yun HJ, Lee JS, et al. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer 2015;14:113.
   PubMed Web of Science ®Google Scholar
• Hsu PC, Yang CT, Jablons DM, et al. The crosstalk between Src and Hippo/YAP signaling pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers 2020;12:1361.
   PubMed Web of Science ®Google Scholar
• Filosto S, Baston DS, Chung S, et al. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther 2013;12:1579–90.
   PubMed Web of Science ®Google Scholar
• Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143–50.
   PubMed Web of Science ®Google Scholar
• Chang S, Yin SL, Wang J, et al. Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. Molecules 2009;14:4166–79.
   PubMed Web of Science ®Google Scholar
• Druker BJ. STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14–S8.
   PubMed Web of Science ®Google Scholar
• Li L, Wang Y, Jiao L, et al. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett 2019;452:191–202.
   PubMed Web of Science ®Google Scholar
• Han H, Li S, Chen T, et al. Targeting HER2 Exon 20 insertion-mutant lung adenocarcinoma with a Novel tyrosine kinase inhibitor mobocertinib. Cancer Res 2021;81:5311–24.
   PubMed Web of Science ®Google Scholar
• Pillonel C. Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors. Pest Manag Sci 2005;61:1069–76.
   PubMed Web of Science ®Google Scholar
• Cui J, Fu R, Zhou LH, et al. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorg Med Chem Lett 2013;23:2442–50.
   PubMed Web of Science ®Google Scholar
• Ture A, Ergul M, Ergul M, et al. Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. Mol Divers 2021;25:1025–50.
   PubMed Web of Science ®Google Scholar
• Vlasov SV, Kovalenko SM, Shynkarenko PE, et al. Synthesis and antimicrobial evaluation of 3-(4-arylthieno[2,3-d]pyrimidin-2-yl)- 2H-chromen-2-ones. Heterocycl Commun 2018;24:237–40.
   Web of Science ®Google Scholar
• Saravanan J, Mohan S, Roy JJ. Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d][ 1,2,3]-triazin-4(3H)-ones as potential antimicrobial agents. Eur J Med Chem 2010;45:4365–9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Li L, et al. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells. J Enzyme Inhib Med Chem 2021;36:1205–16.
   PubMed Web of Science ®Google Scholar
• Agnew-Francis KA, Williams CM. Squaramides as bioisosteres in contemporary drug design. Chem Rev 2020;120:11616–50.
   PubMed Web of Science ®Google Scholar
• Li B, Li Y, Tomkiewicz-Raulet C, et al. Design, synthesis, and biological evaluation of covalent inhibitors of Focal Adhesion Kinase (FAK) against human malignant glioblastoma. J Med Chem 2020;63:12707–24.
   PubMed Web of Science ®Google Scholar
• Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 2011;716:157–68.
   PubMedGoogle Scholar
• Weber H, Müller D, Müller M, et al. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery. J Biomol Screen 2014;19:1350–61.
   PubMedGoogle Scholar
• Asquith CRM, Maffuid KA, Laitinen T, et al. Targeting an EGFR water network with 4-Anilinoquin(az)oline inhibitors for chordoma. ChemMedChem 2019;14:1693–700.
   PubMed Web of Science ®Google Scholar
• Guo T, Ma S. Recent advances in the discovery of multitargeted tyrosine kinase inhibitors as anticancer agents. ChemMedChem 2021;16:600–20.
   PubMed Web of Science ®Google Scholar
• Asquith CRM, Naegeli KM, East MP, et al. Design of a cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. J Med Chem 2019;62:4772–8.
   PubMed Web of Science ®Google Scholar
• Aziz MW, Kamal AM, Mohamed KO, et al. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Bioorg Med Chem Lett 2021;41:127987.
   PubMed Web of Science ®Google Scholar
• Cui Z, Chen S, Wang Y, et al. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur J Med Chem 2017;136:372–81.
   PubMed Web of Science ®Google Scholar
• To C, Jang J, Chen T, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov 2019;9:926–43.
   PubMed Web of Science ®Google Scholar
• Minnelli C, Laudadio E, Mobbili G, et al. Conformational insight on WT- and mutated-EGFR receptor activation and inhibition by epigallocatechin-3-Gallate: over a rational basis for the design of selective non-small-cell lung anticancer agents. Int J Mol Sci 2020;21:1721.
   PubMed Web of Science ®Google Scholar
• Leelananda SP, Lindert S. Computational methods in drug discovery. Beilstein J Org Chem 2016;12:2694–718.
   PubMed Web of Science ®Google Scholar
• Darney K, Lautz LS, Bechaux C, et al. Human variability in polymorphic CYP2D6 metabolism: implications for the risk assessment of chemicals in food and emerging designer drugs. Environ Int 2021;156:106760.
   PubMed Web of Science ®Google Scholar